drugset / Trial / NCT00420927

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

NCT00420927

Phase 4 Completed 1032 enrolled Abbott
RandomizedParallel-groupDouble-blindTreatment

Summary

This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).

Timeline

Start
2006-12
Primary completion
2010-07
Completion
2010-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Background Methotrexate Small molecule 20 mg Oral

Indications